Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter StudyPatrick Cheung, Georg A. Bjarnason, William Chu et al.|European Urology|2021Cited by 128
A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.Patrick Cheung, Georg A. Bjarnason, Samir Patel et al.|Journal of Clinical Oncology|2020Cited by 9